Evotec SE ADR

NASDAQ EVO

Data sourced from

and

Daily

Download Data

Evotec SE ADR Market Capitalization on June 03, 2024: USD 1.76 B

Evotec SE ADR Market Capitalization is USD 1.76 B on June 03, 2024, a -56.32% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Evotec SE ADR 52-week high Market Capitalization is USD 4.73 B on July 20, 2023, which is 168.27% above the current Market Capitalization.
Evotec SE ADR 52-week low Market Capitalization is USD 1.60 B on May 30, 2024, which is -9.05% below the current Market Capitalization.
Evotec SE ADR average Market Capitalization for the last 52 weeks is USD 3.29 B.

NASDAQ: EVO

Evotec SE ADR

CEO	Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.
IPO Date	Dec. 4, 2009
Location	Germany
Headquarters	Essener Bogen 7, Hamburg, Germany, 22419
Employees	5,055
Sector	Healthcare
Industry	Drug manufacturers - specialty & generic

Description

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Key trends